Biotechnology

Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland

- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old pharmaceutical ...

2026-09-14 14:00 2151

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...

2026-09-14 12:38 2086

Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known in Chin...

2026-09-14 10:00 2438

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

* Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). * Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients. * FET-PET imaging is recom...

2026-09-14 06:56 2717

Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026

HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...

2026-09-13 14:59 4024

Agenda for the 4th Hong Kong Clinical-driven Robotics and Embodied AI Technology (CREATE) Symposium Officially Released

Leading Experts from Medicine, Research, Industry and Investment Revealed HONG KONG, Sept. 11, 2026 /PRNewswire/ -- Scheduled for September 22–23, 2026, the 4th Hong Kong Clinical-driven Robotics and Embodied AI Technology (CREATE) Symposium will be held at the Charles K. Kao Auditorium in Hong ...

2026-09-11 19:24 7416

2026 World Laureates Foundation Prize Unveiled in Shanghai

11 WLF Prize laureates; the first time scientists of Chinese descent have been awarded; inaugural WLF Prize for Young Scientists launched. SHANGHAI, Sept. 11, 2026 /PRNewswire/ -- A news report from Yicai Global: On the morning of September 10, the winners of the 2026 World Laureates Foundation ...

2026-09-11 18:24 2477

THE GALIEN FOUNDATION ANNOUNCES INAUGURAL PRIX GALIEN JAPAN FORUM & AWARDS CEREMONY

Prestigious Life Sciences Platform and Awards Launch in Tokyo to Celebrate Breakthrough Innovation TOKYO, Sept. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced that it will host the first Prix Galie...

2026-09-11 08:00 2538

ABEC Opens New Manufacturing Facility in Wilson, North Carolina

Grand Opening Ceremony Scheduled for September 24, 2026 BETHLEHEM, Pa., Sept. 10, 2026 /PRNewswire/ -- ABEC, a global leader in customized solutions and services for biopharmaceutical manufacturing, today announced the grand opening of its newest manufacturing facility in Wilson, North Carolina....

2026-09-10 23:11 2449

TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection

— Phase IIb multicenter trial initiated, bringing this potential life-changing therapy closer to patients — SUZHOU, China, Sept. 10, 2026 /PRNewswire/ -- TenNor Therapeutics, a near-commercial-stage biotechnology company, today announced positive topline results from a Phase IIa proof-of-concept...

2026-09-10 19:30 2639

/C O R R E C T I O N -- CordenPharma/

In the news release, CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year, issued 10-Sep-2026 by CordenPharma over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details ...

2026-09-10 19:28 2538

Nuritas Appoints Former Unilever North America President Kees Kruythoff as Board Chair

The 30-year industry veteran brings global scaling and commercialization expertise to biotech leader Nuritas. DUBLIN, Sept. 10, 2026 /PRNewswire/ -- Nuritas , a global leader in bi...

2026-09-10 19:00 2499

BGI Genomics Launches "Digital Life Twin" Framework to Power Proactive Health

SHENZHEN, China, Sept. 9, 2026 /PRNewswire/ -- Commemorating BGI Group's 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-s...

2026-09-09 21:45 2926

Yuyu Pharma CEO Robert Wonsang Yu Launches "Robert's YUniverse" Podcast

SEOUL, South Korea, Sept. 9, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma, has launched"Robert's YUniverse ", a new podcast series featuring conversations with guests from across culture, business and animal health....

2026-09-09 21:00 4676

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA form...

2026-09-09 21:00 4535

Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...

2026-09-09 20:56 6601

Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...

2026-09-09 20:25 2596

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its su...

2026-09-09 20:00 2129

Daesang Targets Global Pharmaceutical Amino Acid Market, Building on 70 Years of Fermentation Technology

* Leverages fermentation know-how developed through MIWON to expand beyond general-purpose amino acids into high-value pharmaceutical materials * Acquires Germany-based AMINO GmbH, gaining purification technology, European regulatory expertise, and a global customer network SEOUL, South Kore...

2026-09-09 20:00 3551

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited

2026-09-09 19:30 2245
1 ... 567891011 ... 357